Previous 10 | Next 10 |
YONKERS, N.Y., Sept. 18, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that it submitted an Investiga...
YONKERS, N.Y., Aug. 28, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, today announces that Garrett Nichols, M.D., M.S...
2023-08-14 12:49:01 ET Contrafect press release ( NASDAQ: CFRX ): Q2 GAAP EPS of -$1.94 misses by $0.13 . As of June 30, ContraFect had cash and cash equivalents of $14.4M. For further details see: Contrafect GAAP EPS of -$1.94 misses by $0.13
YONKERS, N.Y., Aug. 14, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment...
2023-06-27 10:17:49 ET A clinical-stage biotechnology company, ContraFect ( NASDAQ: CFRX ) enters into a warrant exercise agreement with an existing accredited investor to purchase 7M shares. In connection with the exercise, the company also agreed to reduce the exercis...
YONKERS, N.Y., June 27, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of l...
YONKERS, N.Y., June 20, 2023 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) , a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides as new medical modalities for the treatment of l...
2023-06-12 06:00:00 ET 3 Mistakes That Penny Stocks Traders Make The allure of penny stocks lies in their affordable price and high growth potential. Typically priced under $5 per share, penny stocks present an opportunity for substantial returns, even for investors operating with limit...
2023-06-11 11:00:00 ET 3 Tips for Options Trading With Penny Stocks Penny stocks, low-priced securities of small-cap companies, offer a unique investment landscape brimming with high-growth potential. Their lower price point allows for a wider range of investment possibilities, includin...
2023-06-09 14:37:00 ET Gainers: Blue Apron Holdings ( APRN ) +65% . Sientra ( SIEN ) +50% . ContraFect ( CFRX ) +43% . Global Indemnity ( GBLI ) +23% . Disc Medicine Opco ( IRON ) +21% . Olema Pharmaceuticals ( OLMA ) +...
News, Short Squeeze, Breakout and More Instantly...
ContraFect Corporation Company Name:
CFRX Stock Symbol:
NASDAQ Market:
ContraFect Corporation Website:
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
ContraFect Corporation (CFRX) is expected to report $-0.66 for Q3 2023
Gainers Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares climbed 83.5% to $0.4169 after reporting first-quarter results. Astra Space, Inc. (N...